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With the approval in 2007 of the ﬁrst integrase inhibitor (INI), raltegravir, clinicians became better able to suppress virus
replication in patients infected with human immunodeﬁciency virus type 1 (HIV-1) who were harboring many of the most
highly drug-resistant viruses. Raltegravir also provided clinicians with additional options for ﬁrst-line therapy and for the
simpliﬁcation of regimens in patients with stable virological suppression. Two additional INIs in advanced clinical
development—elvitegravir and S/GSK1349572—may prove equally versatile. However, the INIs have a relatively low genetic
barrier to resistance in that 1 or 2 mutations are capable of causing marked reductions in susceptibility to raltegravir and
elvitegravir, the most well-studied INIs. This perspective reviews the genetic mechanisms of INI resistance and their
implications for initial INI therapy, the treatment of antiretroviral-experienced patients, and regimen simpliﬁcation.
Although the era of highly active anti-
retroviral (ARV) therapy began in 1996,
it was not until a decade later, with the
licensing of 4 new ARVs belonging to
4 ARV classes, that it became possible
to fully suppress HIV-1 replication
in a high proportion of the most
heavily treated HIV-infected individuals.
Darunavir, the protease inhibitor (PI)
with the highest genetic barrier to re-
sistance, and maraviroc, the ﬁrst CCR5
inhibitor, were approved in 2006. Ral-
tegravir (RAL; Merck Laboratories),
the ﬁrst integrase inhibitor (INI), was
approved in 2007, and etravirine, the
ﬁrst non-nucleoside reverse transcriptase
inhibitor (NNRTI) shown to be useful for
treating patients in whom previous
NNRTIs were ineffective, was approved
in 2008. Of these 4 new ARVs, the de-
velopment of RAL may have had the
greatest effect on current ARV treatment
strategies.
RAL, however, may not be unique
among INIs. Two other INIs in advanced
clinical development—elvitegravir (EVG;
Gilead Sciences) and S/GSK1349572
(GlaxoSmithKline)—may be equally ef-
ﬁcacious. However, resistance to RAL
and EVG develops rapidly in vitro and,
in the absence of other active ARVs, in
vivo. Although S/GSK1349572, which is
earlier in its clinical development than
EVG, appears to have a higher genetic
barrier to resistance than RAL or EVG,
its efﬁcacy at treating RAL-resistant vi-
ruses is incomplete. Understanding INI
resistance is therefore critical to use of
INIs for initial therapy, the treatment of
ARV-experienced patients, and regimen
simpliﬁcation.
INTEGRASE STRUCTURE
AND FUNCTION AND
INHIBITOR DISCOVERY
Following reverse transcription, in-
t e g r a s e( I N )c l e a v e st h ec o n s e r v e dd i -
nucleotides GT from the 3# ends of
double-stranded HIV-1 DNA, leaving
2 CA overhangs (the 3#-processing
reaction). IN remains bound to each of
the 3# ends, circularizing the HIV-1
preintegration complex (PIC). IN then
binds the host protein, lens epithelial-
derived growth factor (LEDGF),
which translocates the PIC to the nu-
cleus, where IN catalyzes a nucleo-
philic attack of the viral 3#-hydroxy
ends on the phosphodiester bonds of
host genomic DNA (the strand-
transfer reaction). Although IN cata-
lyzes both the 3#-processing and
strand-transfer reactions, only those
compounds that speciﬁcally inhibit
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INIs. Indeed, the development of
a high-throughput screening assay for
the identiﬁcation of strand-transfer
inhibitors that bind IN in complex with
viral DNA heralded the modern era of
INI development [1].
HIV-1 IN contains 288 amino acids
encoded by the 3# end of the HIV-1 pol
gene. It is composed of 3 functional
domains. The catalytic core domain
(CCD), which encompasses amino acids
51 to 212, contains the catalytic triad
D64, D116, and E152 and the viral DNA
binding site. D64 and D116 coordinate
the positioning of a metallic cationic
cofactor (Mg
11 or Mn
11), which is
essential for IN function. The N-terminal
domain (NTD), which encompasses
amino acids 1 to 50, is characterized by
an HHCC zinc-binding motif. Its pri-
mary role appears to be to facilitate IN
multimerization through its extensive
contacts with adjacent CCD monomers.
The C-terminal domain (CTD), which
encompasses amino acids 213 to 288,
binds host DNA nonspeciﬁcally.
There are published crystal structures
of the HIV-1 IN CCD plus CTD do-
mains, the CCD plus NTD domains, the
CCD bound to LEDGF, and the CCD
bound to an active site inhibitor, the
prototype diketo acid inhibitor 5CITEP
(reviewed in [2–4]; see Figure 1). But the
relative conformation of the CCD, NTD,
and CTD domains and the tetrameric
state of functional HIV-1 IN has been
inferred primarily from crystallographic
studies of the homologous IN of the
prototype foamy virus (PFV) [5]. The
applicability of the PFV IN structure to
HIV-1 IN is validated by the consistency
of the PFV IN structure with HIV-1 IN
biochemical data and by the ability of
PFV IN to co-crystallize with RAL and
EVG [5–6].
HIV-1 IN inhibitors are structurally
diverse molecules that contain a motif
for binding the essential divalent metal
cations Mg
11 or Mn
11 and a hydro-
phobic region for binding within the
cavity formed by integrase and the 3#
HIV-1 DNA ends containing the termi-
nal CA dinucleotide. RAL, EVG, and
S/GSK1349572 displace viral DNA in
the active site and contact several ac-
tive site amino acids—including those in
a mobile loop extending between posi-
tions 140 and 149 [2–4].
INTEGRASE INHIBITOR
RESISTANCE
The principles of INI resistance parallel
those of nucleoside reverse transcriptase
inhibitor (NRTI), NNRTI, and PI re-
sistance: (1) INI resistance is caused by
primary mutations that reduce INI sus-
ceptibility in combination with second-
ary mutations that further decrease virus
susceptibility and/or compensate for the
decreased ﬁtness associated with the
primary mutations; (2) there is a genetic
barrier to INI resistance, deﬁned by
the number of mutations required for
the loss of clinical INI activity; and (3)
there is extensive but incomplete cross-
resistance among the INIs.
Mutations Associated With INI
Resistance
Table 1 summarizes data on 39 muta-
tions at 26 INI positions derived from
(1) in vitro passage experiments in the
presence of RAL [9–10], EVG [7–9], or
572 [11]; (2) in vivo data on mutations
that emerged in individuals receiving
RAL [12–19] or EVG [20]; and (3) in
vitro susceptibility data of site-directed
mutants and clinical HIV-1 isolates to
RAL, EVG, and S/GSK1349572 [7–11,
18, 21–23]. Nineteen mutations at 10
positions (T66IAK, E92QV, F121Y,
Y143RCH, P145S, Q146P, S147G,
Q148HRK, V151AL, and N155HS) re-
duce susceptibility to either RAL or EVG
by 5-fold or higher. Seven of these 19
mutations (E92V, F121Y, P145S, Q146P,
V151AL, and N155S), however, have not
been reported in published sequences
from patients receiving RAL or EVG.
Twenty mutations at 16 additional po-
sitions are accessory mutations that
contribute to INI resistance only in the
presence of primary INI resistance mu-
tations. G140SAC (6E138KA) and
T97A are particularly important acces-
sory mutations because of the marked
contribution these mutations make to
INI resistance and viral ﬁtness in HIV-1
strains containing Q148 [24–26] and
Y143 [18, 21] mutations, respectively.
With the exception of one report of
transmitted INI resistance [27], fewer
than .1% of INI-naive individuals har-
bor viruses with primary INI resistance
mutations [28–29]. As a corollary, nat-
urally occurring resistance to RAL and
the other INIs in advanced clinical de-
velopment is currently absent. Although
secondary INI resistance mutations oc-
cur in INI-naive patients, these muta-
tions do not interfere with the
virological response to RAL-containing
regimens [2, 29–30]. Table 1 does not
show highly polymorphic mutations that
have been only weakly associated with
INI selective drug pressure or decreased
susceptibility such as V72I, T124A,
M154IL, K156N, V165I, V201I, I203M,
T206S, and D232N (reviewed in [28,
31]).
Table 2 shows the most common
patterns of INI resistance mutations in
published HIV-1 IN sequences from
individuals receiving RAL [32]. Among
192 viral isolates from 105 RAL-treated
individuals, 121 viruses contained mu-
tations belonging to one of the 3 most
commonly reported RAL-resistance
mutation pathways: (1) Q148HRK 6
G140SA (n 5 58), (2) N155H 6 E92Q
(n 5 38), and (3) Y143CR 6 T97A (n 5
25). The remaining 71 viruses from 44
individuals included 50 viruses without
primary INI resistance mutations, 18
viruses with mutations belonging to
more than one of the 3 most common
mutational pathways, and 3 with pri-
mary mutations not belonging to any of
the 3 common mutational pathways.
Despite the fact that one mutation such
as Y143R, Q148HKR, or N155H is often
sufﬁcient to reduce RAL susceptibility
more than 10-fold—particularly in si-
te-directed mutagenesis experiments—
PERSPECTIVE d JID d 1205most RAL-resistant viruses obtained
from RAL-treated patients have 2 or
more RAL resistance mutations.
Most published INI susceptibility da-
ta have been produced by Monogram’s
PhenoSense assay, Virco’s Antivirogram
assay, and various permutations of He-
La-CD4
1 reporter gene assays. Although
these assays frequently yield divergent
results, the relative reductions in sus-
ceptibility associated with different mu-
tation patterns is consistent among the
different assays.
Q148 is a critical part of the IN active
site believed to interact with the terminal
adenosine and preterminal cytosine
of the reactive viral DNA strand.
Q148HRK decreases susceptibility to
each of the INIs but also markedly de-
creases IN function. The replication de-
fect associated with Q148HKR, however,
is largely reversed by mutations at po-
sition 140 and, to a lesser extent, at po-
sition 138 [21, 24]. In clinical isolates,
viruses with Q148 plus G140 mutations
have .150-fold reduced susceptibility to
RAL and EVG and up to 10- to 20-fold
reduced susceptibility to S/GSK1349572
particularly when a third INI resistance
mutation is also present (Table 2).
The second-most common pathway to
RAL resistance includes N155H. N155H
lies at the base of the catalytic site, where
it may form a hydrogen bond with the
active site residue E152 and directly
interfere with IN metal binding [2].
N155H reduces susceptibility to RAL
and EVG but not S/GSK1349572.
N155H alone decreases replication ca-
pacity less than that of viruses with Q148
mutations alone. The addition of E92Q
to N155H further decreases RAL and
EVG susceptibility but does not rescue
viral ﬁtness [21]. Therefore, viruses with
N155H 6 E92Q are often outcompeted
by viruses with G140 1 Q148 mutations
[21, 24].
Y143RC is the third-most common
pathway to RAL resistance. When RAL
binds IN, it induces a stacking
interaction with Y143 [5, 34]. Sub-
stitution of Y with C or R removes this
favorable interaction. S/GSK1349572
and EVG do not appear to contact Y143,
and viral susceptibility to these INIs is
not affected by Y143 mutations (Table
2). T97A markedly increases Y143RC-
mediated RAL resistance [18, 21].
Y143H usually occurs as part of an
electrophoretic mixture and may repre-
sent a transition between Y and R (TAC/
T [Y] 5. CAC/T [H] 5. CGC/T [R]).
The Genetic Barrier to INI Resistance
The genetic barrier to INI resistance is
lower than that of the PIs and most
NRTIs. First, INI resistance is usually se-
lected more rapidly during in vitro pas-
sage experiments with INIs than with
most NRTIs and PIs [7–10]. Second, vi-
rological failure on an INI-containing
regimen often occurs within the ﬁrst
several months of therapy and is often
accompanied by INI resistance mutations
[12, 19, 35]. In Merck Protocol 005, 35 of
Figure 1. HIV-1 integrase (IN) inhibitor resistance mutations superimposed on a crystal structure of the IN central core domain bound to a prototype
diketo acid inhibitor (5CITEP; PDB 1QS4) [54]. IN residues 56 to 165 are displayed in gray cartoon mode to represent secondary structural properties.
5CITEP is represented using cyan spheres. Active site residues D64, D116, and D152 are in white. Sites associated with the most commonly occurring
primary mutations are in red (T66, E92, G140, S147, Q148, and N155). Sites associated with the most common accessory mutations (L74, T97, E138,
V151, S153, and S163) and with primary mutations that have been observed solely in vitro (F121, Q145, and P146) are in yellow. Mg
11 is a blue
sphere. Residues 141 to 144, which form part of the highly mobile loop extending between G140 and G149, were not resolved in this crystal structure.
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Effect on Susceptibility to Raltegravir (RAL), Elvitegravir (EVG), and S/GSK1349572 (572)
Wild Type
(Consensus
Subtype B)* Position* Mutation*
Naive*
(%; n5 4,435)
RAL Rx*
(%; n5 105)
RAL
Fold

EVG
Fold

572
Fold

In vitro and
In vivo Selection Data
§
Primary RAL and/or EVG INI Resistance Mutations Observed In vivo
T 66 I 0 0 1 15 1 In vitro and in vivo by EVG [2, 7–8].
A .1 1.8 1 10 1 In vitro and in vivo by EVG [2, 9]
and rarely by RAL [2, 35].
K 0 0 10 80 2 In vitro and in vivo by EVG [2, 9].
E 92 Q 0 8.5 5 30 2 In vitro and in vivo by RAL and EVG
[2, 12–14].
Y 143 C 0 4.8 4 1 1 In vitro and in vivo by RAL [12, 14–16,
19]. Y143H usually occurs as part of
a mixture with Y143RC.
R 0 12 20 1 1
H .1 2.4 2 1 1
S 147 G .1 0 1 8 NA In vitro and in vivo by EVG [2, 7].
Q 148 H 0 35 20 6 1
{ In vitro and in vivo by RAL and EVG
[2, 9, 12, 14–16, 19]
R 0 14 30 100 1
{
K 0 3.8 40 70 1
{
N 155 H 0 46 20 40 1 In vitro and in vivo by RAL and EVG
[2, 12–16, 19].
Primary RAL and/or EVG INI Resistance Mutations Observed Solely In vitro
E 92 V 0 0 3 20 4 In vitro by EVG and GS-9160 [9, 22].
F 121 Y 0 0 5 10 1 In vitro by RAL and EVG [7, 9].
P 145 S 0 0 1 .150 1 In vitro by EVG [9].
Q 146 P 0 0 1 10 NA In vitro by EVG [7].
V 151 A 0 0 5 5 NA In vitro by GS-9160 [22].
L .1 .9 8 30 4 In vitro by L870,812 [9]. Reported in
one patient receiving RAL [16]
N 155 S 0 0 10 40 1 In vitro by S-1360 [9]
Accessory RAL/EVG Resistance Mutations
H 51 Y 0 2.9 3 4 NA In vitro and in vivo by EVG [2, 7] and in
vivo by RAL [18].
V 54 I .5 1.0 1 1 NA In vitro by RAL [10]
L 68 V .8 0 1 1 NA In vivo by EVG [2].
L 74 M 2.5 10 1 1 1 In vivo by RAL usually with N155H
[12, 14–15].
Q 95 K .1 1.9 1 1 NA In vitro by EVG and RAL [2, 7].
T 97 A 2.2 17 1 1 NA In vivo by RAL usually with Y143
mutations [13, 16, 18, 21].
H 114 Y 0 0 1 4 NA In vitro by EVG [8].
T 125 K 0 0 1 1 NA In vitro by L-870,812 [9].
A 128 T .5 1.0 1 1 NA In vitro by RAL and EVG [8, 10].
E 138 K 0.1 1.9 1 1 1 In vitro and in vivo by RAL and EVG
usually with Q148 mutations [2, 35] A 0 3.8 1 1 1
G 140 S .1 36 1 1 1 In vitro and in vivo with Q148HR in
patients receiving RAL [12, 14–16,
19, 35] and EVG [2]. G140AC
is a less well-studied variant in
this position [9, 22].
A 0 2.9 1 1 1
C0 0 1 1 1
V 151 I 2.9 16 1 1 1 In vitro and in vivo by RAL [9, 14,
19, 48]. In vitro by EVG [9].
S 153 Y 0 0 1 3 2.5 In vitro by EVG [2].
E 157 Q 2.0 2.9 2.5 2.5 NA In vitro by EVG [7] and rarely in
vivo by RAL [13].
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veloped RAL-resistant viruses [35], and
in the BENCHMRK trials 64 of 94 with
virological failure who underwent geno-
typic resistance testing had RAL-resistant
viruses [12]. Likewise, a high proportion
of subjects who developed virological
failure while receiving EVG in the phase
II trial GS-153-105 developed EVG-
resistant viruses [2]. Third, the sub-
stitution of RAL for lopinavir/ritonavir
(LPV/r) in the SWITCHMRK trial in
patients with stably suppressed HIV-1
infection was associated with an in-
creased risk of virological rebound [36].
Fourth, although RAL resistance muta-
tions have been associated with decreased
replication capacity [25–26], no clinical
beneﬁt has been observed from continu-
ing RAL in patients with high-level RAL
resistance [37], presumably because most
primary RAL resistance mutations occur
in combination with accessory compen-
satory mutations [24–26].
The genetic barrier to INI resistance,
however, may not be as low as that
of lamivudine, emtricitabine, or the
NNRTIs nevirapine and efavirenz. In
contrast to the NNRTIs, RAL has
been highly effective at treating ARV-
experienced individuals with few thera-
peutic options. In the BENCHMRK
trials, RAL-containing regimens often
Table 1. (Continued)
Wild Type
(Consensus
Subtype B)* Position* Mutation*
Naive*
(%; n5 4,435)
RAL Rx*
(%; n5 105)
RAL
Fold

EVG
Fold

572
Fold

In vitro and
In vivo Selection Data
§
G 163 R .5 8.6 1 1 NA In vivo by RAL [12, 35].
K .4 3.8 NA NA NA
S 230 R .1 3.8 1 1 NA In vitro by RAL and EVG [8].
R 263 K .1 1.9 1 5 NA In vitro by EVG [2]
NOTE. *Direct PCR sequences of HIV-1 group M plasma viruses from 4,435 INI-naive individuals [29]. The RAL-Rx % is the no. of patients with a virus
sequence containing a mutation divided by the number of RAL-treated patients (n 5 105) obtained from 12 published references in the Stanford HIV Drug
Resistance Database [32]. Although several RAL-treated individuals had multiple sequences, no mutation was counted more than once per individual.
In vitro
susceptibility in the absence of other INI resistance mutations. Most data were derived from site-directed mutants. When data were available from multiple
studies or determined using multiple assays the fold resistance approximates the median of the multiple results.
§S-1360, L-870,812, and GS-9160 are
investigational INIs.
{Site-directed mutants with Q148H, Q148R, or Q148K do not decrease 572 susceptibility. However, viruses having one of these mutations in
combination with E138K and/or G140S may have up to 10- to 20-fold decreased 572 susceptibility [11, 33].
Table 2. Phenotypic Susceptibility Data Associated With the Most Common INI Resistance Mutation Patterns Present in 192 Virus
Isolates From 105 Patients
Primary
Mutations*
No. of Unique Viruses
 Published In vitro Susceptibility Data
§
Without accessory
mutations
With accessory
mutations Raltegravir Elvitegravir S/GSK1349572
148H 1 140S 26 18 .150 [2, 9, 11, 21–23] .150 [2, 9, 11, 22–23] 3 [11]
148R 1 140S 5 0 .150 [9, 11, 21, 23] .150 [9, 23] 8 [11]
148R 1 140A 2 1 .150 [21, 23] .150 [23] NA
148R 5 0 10 to 50 [8–9, 11, 21] 90 to 150 [8–9, 11] 1 [11]
148K 1 0 25 to 40 [2, 9–11, 21] 80 [2, 9–11] 1 [11]
Totals 39 19
155H 11 24 10 to 30 [8–11, 21–22] 20 to 50 [2, 8–11, 22] 1 [11]
155H 1 92Q 1 2 80 to 150 [11, 21] 125 to 150 [2, 11] 3 [11]
Totals 12 26
143R 7 1 15 to 20 [11, 21] 2 [11] 1 [11]
143R 1 97A 2 7 .150 [21] NA NA
143C 1 97A 2 4 .150 [18, 21] NA NA
143C 0 2 3 to 4 [11, 21] 1.5 [11] 1 [11]
Totals 11 14
NOTE. The viral sequences in this table were obtained from 12 published references in the Stanford HIV Drug Resistance Database [32].
*G140SA and T97A are in this column because of their strong association with Q148 and Y143 mutations, respectively. Accessory mutations include the
mutations in the second half of Table 1 (except G140SA and T97A). Viruses with primary mutations belonging to more than one pathway are not shown.
The
totals of these 2 columns consist of 121 viruses containing one of the 3 most common raltegravir-associated mutational patterns.
§In vitro susceptibility data
obtained using the PhenoSense assay, the Antivirogram, or one of the generic HeLa-CD4
1 reporter gene assay variants. Viruses containing G140 1 Q148
mutations may have up 10- to 20-fold decreased S/GSK1349572 susceptibility when a third INI resistance mutation is present [11, 33].
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Trial Type Clinical Trial* Trial Design

Virological Outcome and INI
Resistance
Initial ARV Therapy Protocol 004 [38] Phase II randomized blinded
dose-ranging trial of RAL (100,
200, 400, or 600 mg) BID 1
TDF/3TC vs. EFV 1 TDF/3TC
At 2, 4, and 8 weeks, all RAL
treatment arms had a more rapid
plasma HIV-1 RNA decrease than
the EFV arm. At week 48, 84%
of both arms had plasma HIV-1
RNA levels ,50 copies/mL.
STARTMRK [39] Phase III randomized blinded trial
of RAL 1 TDF/FTC (n5 281) vs.
EFV 1 TDF/FTC (n5 282)
Both arms had similar virological
efﬁcacy. Among 84 patients
with VF deﬁned as conﬁrmed
plasma HIV-1 RNA levels .50
copies/mL, 12 of 39 RAL recip-
ients vs. 9 of 45 EFV recipients
had plasma HIV-1 RNA levels
high enough for genotypic
resistance testing. Four of 12
RAL recipients and 5 of 9 EFV
recipients had INI and NNRTI
resistance, respectively [40].
Protocol GS-236-014 [41] Phase II randomized blinded trial
of EVG 1 the novel pharmaco-
kinetic enhancer cobicistat 1
TDF/FTC (‘‘QUAD’’ n5 48) vs.
EFV 1 TDF/FTC (n5 23)
At week 48, 90% of EVG
(‘‘QUAD’’) vs. 83% of EFV
recipients had plasma HIV-1
RNA levels ,50 copies/mL.
SPRING-1 [42] Phase II randomized blinded
dose-ranging trial of 572 (10,
25, or 50 mg) QD (n5 155) vs.
EFV (n5 50) in combination
with TDF/FTC or abacavir/3TC
At 24 weeks, .90% of subjects
in each of the 3 572 arms had
plasma HIV-1 RNA levels ,50
copies/mL.
SPARTAN [43] Pilot randomized open-label study
of RAL 1 ATV 300 mg BID
(n5 63) vs. ATV/r 1 TDF/FTC
QD (n5 31)
Five of 6 RAL-treated subjects
with VF and plasma HIV-1 RNA
levels .400 copies/mL devel-
oped RAL resistance.
PROGRESS [44] Phase III randomized blinded
study of RAL 1 LPV/r (n5 101)
vs. TDF/FTC 1 LPV/r BID
(n 5 105)
One of 4 RAL-treated subjects
with VF and plasma HIV-1 RNA
levels .400 copies/mL devel-
oped RAL resistance.
Regimen Simpliﬁcation EASIER [45] Phase III randomized open-label
trial of RAL vs. continued enfu-
virtide in subjects with plasma
HIV-1 RNA levels ,400 copies/
mL for >3 months
At week 24, 88% of subjects in
both arms had plasma HIV-1
RNA levels ,50 copies/mL. INI
resistance mutations emerged
in 3 of 39 subjects with low-level
viremia (deﬁned as plasma HIV-1
RNA levels ,1,000 copies/mL).
SWITCHMRK 1 and 2 [36] Phase III randomized blinded trial
of RAL (n5 353) vs. continued
LPV/r (n5 354) in subjects with
plasma HIV-1 RNA levels ,50
copies/mL for >3 months
At week 24, 84.4% of subjects
receiving RAL vs. 90.6%
receiving LPV/r maintained
plasma HIV-1 RNA levels ,50
copies/mL. Eight of 11 RAL-
treated subjects with VF and
plasma HIV-1 RNA levels .400
copies/mL developed RAL re-
sistance mutations.
SPIRAL [46] Phase IV 48-week randomized
open-label trial of RAL 400 vs.
continued RTV-boosted PI in
subjects with plasma HIV-1
RNA levels ,50 copies/mL for
>6 months
At week 48, 89.2% of subjects
receiving RAL vs. 86.6%
receiving continued RTV-
boosted PI maintained plasma
HIV-1 RNA levels ,50 copies/
mL. Week 48 RAL resistance
data were not described.
ODIS [47] Pilot open-label randomized trial of
RAL 800 mg QD (n5 177) vs.
RAL 400 mg BID (n5 35) as
a substitute for continued RTV-
boosted PI in subjects with
plasma HIV-1 RNA levels ,50
copies/mL for >6 months
At week 24, 6.4% of those
receiving RAL QD vs. 2.9% of
those receiving RAL BID
(P 5 .2) had virological failure.
All but one virological failure
occurred in patients with a his-
tory of prior NRTI resistance.
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sion despite the absence of other highly
active ARVs [12]. In addition, most
patients with low-level virological
rebound while receiving RAL do not
develop INI resistance mutations. For
example, none of the 14 subjects in the
ANRS 139 TRIO trial with virological
rebound developed INI resistance
mutations [30] (Table 3). It has also
been extremely difﬁcult to select for
S/GSK1349572 resistance in vitro,
Table 3. (Continued)
Trial Type Clinical Trial* Trial Design

Virological Outcome and INI
Resistance
Late-Stage Therapy: INI Naive Protocol 005 [48] Phase II blinded dose-ranging trial
of RAL 200, 400, or 600 mg BID
1 OBR (n5 133) vs. placebo 1
OBR (n5 45)
At 24 weeks, the mean plasma
HIV-1 RNA decrease was .1.8
log copies/mL in each of the
RAL recipients vs. .35 log cop-
ies/mL in the placebo recipi-
ents. Among 38 RAL recipients
with VF, 35 had RAL resistance
[35].
BENCHMRK 1 and 2 [12] Phase III randomized blinded trials
of RAL (n5 462) vs. placebo
(n5 267) 1 OBR in subjects
with 3-class resistant virus
At week 16, 62% of RAL recipi
ents vs. 35% of placebo recip-
ients had plasma HIV-1 RNA
levels ,50 copies/mL. Sixty-
four of 94 subjects with VF had
RAL resistance to IN mutations
at positions 143, 148, or 155
usually in combination with one
or more accessory INI resis-
tance mutations.
ANRS 139 TRIO [49] Phase II open-label trial of RAL 1
DRV/r 1 etravirine 1 OBR in
subjects with 3-class resistant
virus (n5 103)
At week 48, 86% had plasma
HIV-1 RNA levels ,50 copies/
mL. The 14 subjects with VF
generally had low-level viremia
(median plasma HIV-1 RNA
levels of 90 copies/mL); none
had INI resistance mutations
[30].
Protocol GS-183-105 [20] Phase IIb randomized dose-
ranging trial of RTV (100 mg)-
boosted EVG (20, 50, or 125
mg) QD 1 OBR (n5 205) vs.
RTV-boosted PI 1 OBR
(n5 73). Adding DRV or TPV to
EVG/r was permitted later in the
trial and used after week 16.
The EVG 20 mg arm was
discontinued at week 8. The
125 mg EVG dosage regimen
produced a signiﬁcantly greater
decrease in plasma HIV-1 RNA
levels than the comparator RTV-
boosted PI arm. However,
plasma HIV-1 RNA levels ,50
copies/mL occurred mainly in
those EVG recipients who also
received enfuvirtide or subse-
quently added TPV or DRV. EVG
resistance occurred commonly
among EVG recipients with VF.
Late-Stage Therapy: INI
Experienced
VIKING [33] Phase II single-arm study of 572
50 mg QD as RAL replacement 3
10 days followed by 572 50 mg 1
OBR 3 23 weeks (n5 27). The
initial primary end point was
a plasma HIV-1 RNA decrease >.7
logs by day 11.
In the 18 subjects with viruses
having mutations belonging to
the N155H or Y143 pathways,
the mean plasma HIV-1 RNA
decrease by day 11 was 1.8 log
copies/mL. Three of 5 subjects
with Q148H 1 G140S had an
RNA decrease >.7 logs by day
11. None of 4 subjects with
a Q148 mutation plus >2 addi-
tional mutations at positions 74,
138, and 140 had an RNA
decrease >.7 logs.
NOTE. RAL, raltegravir; EVG, elvitegravir; 572, S/GSK1349572; TDF, tenofovir; 3TC, lamivudine; FTC, emtricitabine; EFV, efavirenz; RTV, ritonavir; ATV,
atazanavir; TPV, tipranavir; DRV, darunavir; LPV/r, lopinavir/ritonavir; ARV, antiretroviral; BID, twice daily; INI, integrase inhibitor; NRTI, nucleoside reverse
transcriptase inhibitor; NNRTI, nonnucleoside reverse transcriptase inhibitor; OBR, optimized background regimen; PI, protease inhibitor; QD, once daily; VF,
virological >failure.
*Clinical trials are ordered according to their year of publication.
Raltegravir dosage was 400 mg twice daily unless otherwise speciﬁed. Other regimens and
antiretrovirals were used at standard dosages unless otherwise speciﬁed.
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genetic barrier to resistance than RAL or
EVG [11].
INI Cross-Resistance
The 2 most commonly occurring RA-
L-associated mutation pathways—
Q148HRK 1 G140SAC and N155H 6
E92Q—both cause high-level EVG re-
sistance. In contrast, the third RAL-
associated mutation pathway, Y143CR 6
T97A, does not confer EVG cross-
resistance. Similarly, the common EVG-
associated resistance mutations T66I
[8–9] and S147G [2, 7] do not confer
RAL cross-resistance. S/GSK1349572 is
fully active in vitro against viruses with
N155H 6 E92Q or Y143CR 6 T97A.
However, susceptibility to S/GSK1349572
is reduced by about 10- to 20-fold by
mutations at positions Q148HRK 6
G140SAC 6 E138KA [11, 33].
CLINICAL IMPLICATIONS OF
INTEGRASE INHIBITOR
RESISTANCE
RAL was ﬁrst approved because of
its effectiveness in the treatment of 3-
and 4-class experienced HIV-infected
individuals. It was subsequently ap-
proved for ﬁrst-line therapy because of
the noninferiority of tenofovir (TDF) 1
emtricitabine (FTC) 1 RAL compared
with the standard-of-care ﬁrst-line regi-
men TDF 1 FTC 1 efavirenz (EFV).
RAL has since found a third role as
a well-tolerated substitute for enfuvirtide
or ritonavir-boosted PIs in patients with
stable virological suppression (‘‘regimen
simpliﬁcation’’).
The novel stage at which INIs block
HIV-1 replication has prompted in-
tensiﬁcation studies designed to eradicate
HIV-1 from long-lived cellular reservoirs
or to eliminate low-level residual vire-
mia that emanates from this reservoir.
These studies have shown that RAL in-
tensiﬁcation does not appear to reduce
the size of the latent virus reservoir or
eliminate low-level residual viremia
[50–52]. One study has shown that in
some patients the latent HIV-1 reservoir
is replenished by ongoing low-level rep-
lication because telltale episomal viral
forms accumulate in some patients re-
ceiving RAL intensiﬁcation [53].
Initial ARV Therapy
Table 3 summarizes published clinical
trials in which INIs were used for initial
ARV therapy [38–39, 41–44]. In the phase
III STARTMRK trials, RAL 1 TDF/FTC
twice daily was as effective as the stan-
dard-of-care regimen (EFV 1 TDF/FTC
o n c ed a i l y )[ 3 9 ] .A sar e s u l t ,p u b l i s h e d
guidelines have recommended RAL 1
TDF/FTC as a preferred ﬁrst-line regimen.
In a viral dynamic substudy of the
phase II trial Protocol 004 [38], RAL-
containing treatment was shown to ac-
celerate the decline in plasma HIV-1
RNA levels relative to EFV-containing
treatment. The accelerated decline in
virus levels appears to result from INI-
induced prevention of the release and
production of virions from cells with
unintegrated forms of HIV-1 DNA. This
accelerated decline, however, has not
been shown to provide a unique clinical
beneﬁt presumably because the longer
period of detectable viremia in patients
not receiving INIs is caused by virions
produced from unintegrated viral DNA
that are unable to infect new cells in the
presence of active reverse transcriptase
or protease inhibition.
In an interim 48-week analysis of the
phase IIb trial comparing 48 subjects
receiving EVG 1 cobicistat (an in-
vestigational pharmacokinetic enhancer) 1
TDF/FTC with 23 subjects receiving EFV
1 TDF/FTC, the EVG- and EFV-
containing arms demonstrated similar
virological efﬁcacy [41]. In a dose-
r a n g i n g2 4 - w e e kp h a s eI Is t u d yo fS /
GSK1349572, at least 90% of subjects re-
ceiving each of the 3 S/GSK1349572 dos-
ages had plasma HIV-1 RNA levels below
50 copies/mL [42].
In the NRTI-sparing PROGRESS trial,
RAL 400 mg BID 1 LPV/r 400/100 mg
BID produced virological responses
similar to the standard-of-care regimen
TDF/FTC 1 LPV/r 400/100 mg BID
[44] (Table 3). Four subjects in the RAL-
containing arm met the protocol-de-
ﬁned criteria for virological failure and
genotypic resistance testing, and one had
INI resistance. In the 24-week NRTI-
sparing SPARTAN trial, open-label RAL
400 mg BID 1 atazanavir (ATV) 300 mg
BID in 63 patients was similar in efﬁcacy
to the standard-of-care arm (ATV/r 1
TDF/FTC) [43]. However, among the 11
RAL recipients with virological failure, 5
developed RAL resistance, suggesting
that despite the clinical efﬁcacy of RAL
1 ATV, the regimen may be associated
with a higher risk of INI resistance at the
time of virological failure. The clinical
trial was halted because of the frequent
occurrence of INI resistance and hyper-
bilirubinemia [43].
Regimen Simplification
One controlled comparative trial [45]
and multiple open-label pilot studies
have shown that patients with stable vi-
rological suppression on an enfuvirtide-
containing regimen can substitute RAL
for enfuvirtide without risking virologi-
cal rebound. The substitution of RAL for
a boosted PI, however, has not been
uniformly successful. In the large ran-
domized double-blinded controlled
SWITCHMRK trial, RAL regimen sim-
pliﬁcation was less efﬁcacious than con-
tinued LPV/r: 84% of 353 RAL recipients
versus 91% of 354 suppressed subjects
continuing LPV/r maintained a plasma
HIV-1 RNA level of fewer than 50
copies/mL by week 24 [36]. Moreover, 8
of the 11 RAL recipients with virological
failure developed RAL resistance. In
contrast, in the phase IV open-label
SPIRAL trial, RAL substitution was at
least as efﬁcacious as the boosted PI arm:
89% versus 87% of subjects, respectively,
maintained plasma HIV-1 RNA levels
of fewer than 50 copies/mL over the
48-week study period [46].
The higher risk of virological fail-
ure associated with RAL in the
SWITCHMRK compared with the SPI-
RAL trial is consistent with the
PERSPECTIVE d JID d 1211observation that failure in SWITCHMRK
was associated with previous NRTI fail-
ure, so LPV/r was more effective than
RAL in the context of a compromised
background regimen. In contrast, in the
SPIRAL trial about one-half of the sub-
jects in the comparator arm received
ATV/r and fosamprenavir/r, PIs with
a lower genetic barrier to resistance than
LPV/r. Subjects in the SPIRAL trial
also had a longer baseline history of
virological suppression (>6m o n t h s
versus >3 months) than those in the
SWITCHMRK trial, placing the SPIRAL
trial participants at a lower risk of
virological failure.
ARV-Experienced Patients
The phase III randomized double-blind
controlled BENCHMRK trial demon-
strated the efﬁcacy of RAL for highly
ARV-experienced patients (Table 3).
The phase II GS-183-105 trial compared
several different ritonavir-boosted EVG
(EVG/r) dosages with an optimized
ritonavir-boosted PI-containing regi-
men. In GS-183-105, the superiority of
EVG/r relative to the comparator arm
was less than that in the BENCHMRK
trials because in GS-183-105, EVG/r
was compared with a boosted PI and
an optimized background regimen. In
contrast, in the BENCHMRK trials,
RAL was compared solely with an
optimized background regimen. A dou-
ble-blinded phase III study directly
comparing the safety and efﬁcacy of
EVG/r with RAL has been fully enrolled
(NCT00708162).
Although the treatment of highly
ARV-experienced patients with ARV
regimens containing RAL or EVG has
been successful in the majority of pa-
tients in these trials, virological failure
and INI resistance occurred in a large
proportion of subjects whose optimized
background regimen contained no addi-
tional active ARVs. The successful use of
RAL for treating highly ARV-experienced
patients in clinical practice has also been
high, particularly when it is part of
a regimen containing one or more
recently approved ARVs such as dar-
unavir, maraviroc, or etravirine [49].
The VIKING trial is a phase II
single-arm study of S/GSK1349572 QD
administered to subjects with RAL-
resistant viruses in whom a previous
RAL-containing regimen had been un-
successful [33]. For the ﬁrst 10 days of
the trial, S/GSK1349572 was given as
functional monotherapy (ie, in combi-
nation with existing ARVs for those
subjects who had already discontinued
RAL or as replacement for RAL for those
subjects still receiving it). In the 18
subjects with viruses having mutations
in the N155 or Y143 mutational path-
ways, the mean RNA decrease was 1.8
logs by day 11. In contrast, the virolog-
ical response was poorer in patients with
viruses having Q148 pathway mutations.
Although 3 of 5 subjects with Q148H 1
G140S had an RNA decrease >.7 logs by
day 11 (the primary end point), none of
4 subjects with a Q148 mutation plus 2
or more additional mutations at posi-
tions 74, 138, and 140 had an RNA de-
crease >.7 logs. Whether or not the 10-
to 20-fold decreased susceptibility to S/
GSK1349572 associated with a Q148
mutation plus one or more mutations
can be overcome with a higher S/
GSK1349572 dosage (50 mg twice daily)
is being evaluated in a second cohort of
this trial (NCT00950859; http://clinical-
trials.gov).
There have been no studies of RAL or
EVG in patients infected with viruses
containing INI resistance mutations or
having a history of previous INI therapy.
Therefore, there are no clinically vali-
dated genotypic susceptibility scores or
phenotypic cutoffs yet for these INIs.
However, treatment with RAL is unlikely
to be effective at treating viruses con-
taining one of the major RAL resistance
mutations such as Y143CR, Q148HRK,
and N155H. Likewise, treatment with
EVG is unlikely to be effective at
treating viruses containing one of the
major EVG resistance mutations such as
T66IAK, E92Q, S147G, Q148HRK, and
N155H.
CONCLUSIONS
The potency and tolerability of RAL
have made it an important option for
ﬁrst-line therapy, the treatment of highly
ARV-experienced patients, and regimen
simpliﬁcation. RAL’s relatively low ge-
netic barrier to resistance, coupled with
the high level of cross-resistance within
the INI class, calls for clinicians to be
familiar with the studies that deﬁne
RAL’s optimal use. The investigational
INIs EVG and S/GSK1349572 are also
being studied for ﬁrst-line therapy and
the treatment of highly ARV-experienced
patients. If these INIs are approved and
prove to be as well tolerated as RAL, they
are also likely to be used for regimen
simpliﬁcation. S/GSK1349572 may also
prove useful at treating a signiﬁcant
subset of patients who have RAL-
resistant viruses.
This study was supported by NIH
grants AI46148 and AI068581. J.-L.B.
was supported in part by the Spanish
Infectious Diseases Society.
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